Clinical Validity of Next-Generation Sequencing Multi-Gene Panel Testing for Detecting Pathogenic Variants in Patients With Hereditary Breast-Ovarian Cancer Syndrome
Annals of Laboratory Medicine
;
: 148-154, 2020.
Article
in English
| WPRIM
| ID: wpr-762472
ABSTRACT
BACKGROUND:
Hereditary breast and ovarian cancer syndrome (HBOC) is caused by pathogenic variants in BRCA and other cancer-related genes. We analyzed variants in BRCA gene and other cancer-related genes in HBOC patients to evaluate the clinical validity of next-generation sequencing (NGS) multi-gene panel testing.METHODS:
The BRCA1/2 NGS testing was conducted for 262 HBOC patients. Multiplex ligation-dependent probe amplification and direct Sanger sequencing were performed for confirmation. Multi-gene panel testing was conducted for 120 patients who did not possess BRCA1/2 pathogenic variants but met the National Comprehensive Cancer Network criteria.RESULTS:
Pathogenic variants in BRCA1/2 were detected in 30 HBOC patients (11.5%). Additionally, four out of the 120 patients possessed pathogenic variants by multi-gene panel testing (3.3%) MSH2 (c.256G>T, p.Glu86*), PMS2 (c.1687C>T, p.Arg563*), CHEK2 (c.546C>A, p.Tyr182*), and PALB2 (c.3351-1G>C). All the four patients had a family history of cancer.CONCLUSIONS:
Multi-gene panel testing could be a significant screening tool for HBOC patients, especially for those with a family history of cancer.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Mass Screening
/
Hereditary Breast and Ovarian Cancer Syndrome
/
Multiplex Polymerase Chain Reaction
Type of study:
Prognostic study
/
Screening study
Limits:
Humans
Language:
English
Journal:
Annals of Laboratory Medicine
Year:
2020
Type:
Article
Similar
MEDLINE
...
LILACS
LIS